Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080565 | 0.78 | MAPT (0.35) | RECQLMAPTALDH1A1HPGDGAA | |
| SCHEMBL7080563 | 0.78 | MAPT (0.35) | RECQLMAPTALDH1A1HPGDGAA | |
| SCHEMBL30655454 | 0.71 | MAPT (0.37) | RECQLMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3965977 | 0.71 | MAPT (0.47) | RECQLMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL3965975 | 0.71 | MAPT (0.47) | RECQLMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL3966403 | 0.71 | MAPT (0.47) | RECQLMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL17318680 | 0.71 | RECQL (0.45) | RECQLMAPTALDH1A1TSHRGAA | |
| SCHEMBL17318679 | 0.71 | RECQL (0.45) | RECQLMAPTALDH1A1TSHRGAA | |
| SCHEMBL17318678 | 0.71 | RECQL (0.45) | RECQLMAPTALDH1A1TSHRGAA | |
| SCHEMBL6523258 | 0.70 | PRKDC (0.49) | MAPTKDM4EALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | RECQL 3008/4885MAPT 164/4885KDM4E 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.